COMMUNIQUÉS West-GlobeNewswire

electroCore Provides Update on 510(k) Submission Seeking Expanded Indication for gammaCore™
25/09/2019
Additional information requested by FDA; Premium 2 trial progressing as planned BASKING RIDGE, N.J., Sept. 25, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR, or the “Company”), a commercial-stage [...]
GBT Announces Participation at the 2019 Cantor Global Healthcare Conference
25/09/2019
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2019 Cantor Global Healthcare Conference in New York City [...]
TYME Launches Pivotal Stage of TYME-88-PANC Trial to Evaluate SM-88 for Third-Line Treatment of Patients with Metastatic Pancreatic Cancer
25/09/2019
Oral SM-88 represents a new approach designed to selectively disrupt protein synthesis in cancers with demonstrated responses in 15 different cancer types across four separate studies Data presented at ESMO GI 2019 from [...]
Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology Patent
25/09/2019
Leveraging Growing Patent Estate Creates Value and Strengthens Core Competency HOUSTON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary [...]
AMAG Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
25/09/2019
WALTHAM, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will participate in the Cantor Fitzgerald Global Healthcare Conference in New York on Thursday, October 3, 2019. Ted Myles, [...]
Vaxart’s Tableted Oral Bivalent Norovirus Vaccine Meets Primary and Secondary Endpoints in Phase 1b Study
25/09/2019
Both norovirus vaccines induced substantial immune responses with no indication of immunological interference when administered concurrently Phase 2-ready oral norovirus vaccine targets potential $3B+ market opportunity [...]
resTORbio to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
25/09/2019
BOSTON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related [...]
SIGA Technologies CSO to Speak at The 13th CBRNe Protection Symposium on September 25, 2019
25/09/2019
NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis E. Hruby, the [...]
VitalHub Corp. Announces Early Redemption Of $2,219,000 Outstanding Debentures & New Debt Financing
25/09/2019
TORONTO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- VITALHUB CORP. (TSXV: VHI) (the “ Company ” or “ VitalHub ”) is pleased to announce that it has redeemed in full the $2,219,000 aggregate principal amount of outstanding [...]
Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference
25/09/2019
SAN DIEGO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for [...]
Dance Biopharm Announces Rebranding to Aerami Therapeutics Reflecting a Broadened Strategic Focus on Inhaled Therapies for Chronic Diseases
25/09/2019
Aerami is exploring inhaled therapies beyond human insulin in multiple chronic conditions Launched three new pipeline programs aimed at treatment of type 2 diabetes, hypoparathyroidism and human growth hormone [...]
AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients
25/09/2019
Excellent safety results seen in CF patients, with CFA in line with previous studies and no need for a protease Management to discuss the results on a call scheduled for today, September 25, 2019 at 8:30 a.m. Eastern [...]
T2 Biosystems Enters into Distribution Agreement to Expand its Innovative Rapid Diagnostic Technologies to Puerto Rico and the U.S. Virgin Islands
25/09/2019
LEXINGTON, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it [...]
Cytokinetics Announces Second Annual Communications Fellowship Program Call for Proposals
25/09/2019
Grants Support Community Engagement for Patient Advocacy Organizations Focused on Cardiovascular or Neuromuscular Diseases Deadline for Applications is November 15 th , 2019 SOUTH SAN FRANCISCO, Calif., Sept. 25, 2019 ( [...]
Intra-Cellular Therapies Announces Progression to Higher Dose Cohort in ITI-214 Translational Medicine Study in Patients with Heart Failure
25/09/2019
Data indicate ITI-214 at a dose of 30 mg is well tolerated with a favorable safety profile Study ‘104 now proceeding to a third cohort at a dose of 90 mg NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular [...]
RTI Surgical® Showcases Advancements in Spine Portfolio and Clinical Data at NASS 2019
25/09/2019
RTI announces interim clinical outcomes on 150 patients at 6-month follow-up in the EVoluSIon study for the SImmetry® Sacroiliac Joint Fusion System showing statistically significant reductions in pain of 56% and opioid [...]
Trillium Therapeutics Appoints Jan Skvarka as President and Chief Executive Officer
25/09/2019
Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) TORONTO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative [...]
Microbix Presenting at Muskoka Capital Conference
25/09/2019
Meetings with Growth-Oriented Investors, September 27-29, 2019 MISSISSAUGA, Ontario, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of clinical diagnostic materials and [...]
Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria
25/09/2019
– Danicopan Phase 2 PNH combination therapy topline data expected Q4 2019 – – Initiation of Phase 3 planned for early 2020 – BLUE BELL, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: [...]

Pages